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Abstract
Rationale — The cannabinoid CB1 receptor antagonist/inverse
agonist rimonabant (SR 141716) has been shown to block
reinforcing and rewarding effects of nicotine. Research
has not investigated whether the cannabinoid system is
involved in the interoceptive stimulus effects of nicotine
functioning as a conditional stimulus (CS).
Objective — We examined the effects of rimonabant and the
CB1/2 receptor agonist, CP 55,940, on responding evoked
by a nicotine CS in rats. Additionally, we determined
whether CP 55,940 functioned as a CS or a Pavlovian positive drug feature
Materials and methods — Pavlovian discrimination training involved intermixed nicotine (0.2 mg base/kg) and saline
sessions with intermittent access to water only on nicotine.
Antagonism tests with rimonabant (0.1-3 mg/kg) and substitution tests with CP 55,940 (0.003–0.1 mg/kg) followed.
An effective dose of CP 55,940 was tested against the nicotine generalization curve. A separate group received CS
training with CP 55,940 (0.01 mg/kg). Two other groups
were trained using CP 55,940 (0.01 or 0.03 mg/kg) as a positive drug feature in which a brief light CS signaled access
to water only on CP 55,940 sessions
Results — Rimonabant blocked nicotine-evoked responding.
CP 55,940 partially substituted for nicotine and enhanced
responding to lower nicotine doses. Overall, CP 55,940 did
not acquire control of conditioned responding in either
Pavlovian drug discrimination task
Conclusions — The cannabinoid system was involved in the
CS effects of nicotine. This finding is counter to the operant
drug discrimination research with nicotine as a discriminative stimulus, warranting further research into this possible dissociation.

Introduction
Recent attention has been given to cannabinoid compounds for use in smoking cessation. Of particular interest have been compounds related to the cannabinoid
CB1 receptor antagonist/inverse agonist rimonabant,
or SR 141716. Cannabinoid antagonists have appeared
promising for use as smoking pharmacotherapies, and
several pharmaceutical companies have worked to develop a marketable compound. For example, another
CB1 antagonist, surinabant (SR 147778; Lamota et al.
2008; Rinaldi-Carmona et al. 2004) completed Phase II
clinical trials in Europe in 2008 before development was
discontinued because of adverse side effects.
Preclinical findings in rodents describing the role of
cannabinoid activation on behavioral effects of nicotine have been reviewed elsewhere (e.g., Beardsley and
Thomas 2005; Castañé et al. 2005). Briefly, rimonabant
has been found to decrease nicotine self-administration
(Cohen et al. 2002; Kodas et al. 2007), cue-induced reinstatement of nicotine seeking (Cohen et al. 2004; De Vries et al. 2005), and nicotine-conditioned place preferences (Forget et al. 2005; Le Foll and Goldberg 2004).
The operant discriminative stimulus (SD) effects of nicotine do not appear to be affected by pretreatment with
rimonabant (Cohen et al. 2002; Le Foll and Goldberg
2004; Zaniewska et al. 2006).
655
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These cannabinoid effects on nicotine led us to examine the potential role for cannabinoid activation in the
expression of the conditional stimulus (CS) effects of
nicotine in an appetitive Pavlovian conditioning task (cf.
Besheer et al. 2004). In this task, rats receive a subcutaneous (SC) injection of nicotine or saline before placement in a conditioning chamber. On nicotine sessions,
liquid sucrose (i.e., the unconditioned stimulus; US) is
delivered intermittently. Sucrose is not available on intermixed saline sessions. Using head entries into the
sucrose receptacle before the first sucrose delivery as
a measure of the conditioned response (i.e., CR; goal
tracking; Farwell and Ayres 1979), nicotine serves as an
interoceptive CS as evidenced by increased dipper entries on nicotine compared to saline sessions. The most
notable procedural distinction between this task and the
operant drug discrimination models is that there is no
explicit response requirement for reinforcement to be
delivered in the discriminated goal-tracking task. Although a rat must insert its head into the dipper to access the sucrose, the delivery of the sucrose is determined by the experimenter—not the rat. Recent research
suggests that the CS effects of nicotine might involve
somewhat different neuropharmacological processes
than that of a SD. Specifically, N-methyl-d-aspartate receptor blockade attenuated conditioned responding
evoked by a nicotine CS (Murray and Bevins 2007a), but
has not been shown to affect operant responding controlled by SD effects of nicotine (Kim and Brioni 1995;
Zakharova et al. 2005).Therefore, we examined the effects of the cannabinoid CB1 receptor antagonist/inverse
agonist, rimonabant (Pan et al. 1998; Rinaldi-Carmona et
al. 1994) and the non-selective cannabinoid CB1/2 receptor agonist, CP 55,940 (Little et al. 1988; Thomas et al.
1998) on nicotine-evoked conditioned responding. We
also examined whether CP 55,940 served as a CS or as a
Pavlovian drug feature.
Materials and methods
Subjects For all experiments, we used male Sprague–
Dawley rats (314 ± 10 g at start of study) from Harlan
(Indianapolis, IN, USA) that were previously used in
brief cocaine/novelty place conditioning experiments
(Reichel and Bevins 2008; unpublished research). Rats
were taken from control and low-dose cocaine groups;
care was taken to match histories as much as possible
across the different conditions of the present report. Before the start of the present studies, rats were handled
for at least 3 min/day for 3 days. They were housed individually in clear 48.3 × 26.7 × 20.3 cm (l × w × h) polycarbonate cages lined with wood shavings in a temperature- and humidity-controlled colony. Food was
continuously available in the home cage. Rats were 23h water-restricted; access to water for the hour occurred
after each daily session. All sessions were conducted
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during the light portion of a 12-h light:dark cycle with
lights on at 0600 h. Protocols were approved by the University of Nebraska-Lincoln Animal Care and Use Committee and followed the “Guidelines for the Care and
Use of Mammals in Neuroscience and Behavioral Research” (National Research Council 2003).
Apparatus Eight conditioning chambers (ENV-008CT;
Med Associates, Inc., St. Albans, VT, USA) measuring
30.5 × 24.1 × 21.0 cm (l × w × h) were used. Sidewalls
were aluminum; the ceiling and front and back walls
were clear polycarbonate. Each chamber was equipped
with a recessed receptacle (5.2 × 5.2 × 3.8 cm; l × w × d)
on one sidewall. A dipper arm raised a 0.1-ml cup of
distilled water into the receptacle. Water, rather than
sucrose, served as the US because cannabinoid compounds can affect caloric consumption (e.g., Glick and
Milloy 1972; Xie et al. 2007). An infrared emitter/detector unit, 1.2 cm into the receptacle and 3 cm above the
chamber floor, monitored head entries into the dipper.
A second infrared emitter/detector unit, 4 cm above
the rod floor, bisected the chamber 14.5 cm from the
sidewall containing the receptacle. This unit provided
a measure of locomotor activity in the chamber. Two
white stimulus lights (2.54 cm diameter; 28 V, 100 mA)
were each mounted on the sidewall on either side of
the dipper receptacle, 14.6 cm above the metal rod floor
and 3.5 cm from either the front or the back wall. Illumination of the lights served as the discrete CS in the
CP 55,940 positive feature experiments. Each chamber
was enclosed in a light- and sound-attenuating cubicle
fitted with a fan to provide airflow and mask noise. A
personal computer with Med Associates interface and
software (Med-PC for Windows, version IV) controlled
water deliveries and recorded dipper entries and locomotor activity.
Drugs (−)-Nicotine hydrogen tartrate (Sigma, St. Louis,
MO, USA), rimonabant (RTI International, Research Triangle Park, NC, USA), and CP 55,940 (RTI International)
were used. Nicotine was mixed in saline then adjusted
to a pH of 7.0 ± 0.2. Rimonabant and CP 55,940 were
mixed in a 1:1:18 Tween-80: 100% ethanol: distilled water vehicle. Nicotine was injected subcutaneously (SC)
at 1 ml/kg with a 5-min injection-to-placement interval
(IPI). Rimonabant and CP 55,940 were injected intraperitoneally (IP). Rimonabant was given at 2 ml/kg with a
40 min IPI (cf. Wiley et al. 1995a); CP 55,940 was given
at a volume of 1 ml/kg with a 30 min IPI (cf. De Vry and
Jentzsch 2003; Mauler et al. 2002). Nicotine doses are reported in base form.
Nicotine CS training and testing Rats (n = 16) were given
an injection of 0.2 mg/kg nicotine each day for 3 days in
the home cage to attenuate the initial locomotor suppressant effects of nicotine (cf. Murray and Bevins 2007a).
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Daily training sessions began the day after the last nicotine injection. Rats received either 0.2 mg/kg nicotine
or saline before the start of each 20-min session. During
nicotine sessions, there were 36 deliveries of 4 s access
to water. Four different programs that varied when water was delivered were created to discourage timing of
water deliveries. The average time before the first water delivery across programs was 137 s with a range of
124–152 s. No water was delivered during saline sessions, but there were 4-s “empty” intervals to maintain
consistency between nicotine and saline sessions. Session types and programs were randomly assigned with
the restriction that no more than two nicotine or two saline sessions occurred in a row. Training continued for
28 sessions. Following acquisition of the discrimination,
rats entered testing. On the first four consecutive days
of each 5-day cycle, rats received two nicotine and two
saline training sessions as described previously. If the
discrimination criterion was met (see later), a 4-min test
session occurred in place of a training session on day 5;
water was withheld in testing. If the criterion was not
met, the rat remained in its home cage on that day. Nicotine generalization was tested first, followed by tests
of rimonabant antagonism then CP 55,940 substitution.
Finally, nicotine generalization was conducted again
concurrently with CP 55,940 pretreatment of the nicotine dose–effect curve. Within each phase, the test doses
were randomly intermixed for each rat. All ligands and
doses in a phase were completed before beginning the
next phase.
CP 55,940 CS training A separate set of rats (n = 16) received either 0.01 mg/kg CP 55,940 or vehicle before
each 20-min session. Water was delivered only in the CP
55,940 sessions. The programs and their order were the
same as the nicotine CS experiment. Following 56 sessions of training with the CP 55,940 CS, rats were randomly assigned to one of two groups. One group remained with CP 55,940 training as described for another
eight CP 55,940 and eight vehicle sessions. The other
group was switched from CP 55,940 training to 0.2 mg/
kg nicotine training for eight nicotine and eight saline
sessions.
CP 55,940 feature-positive training Rats (0.01/0.03 mg/
kg group, n = 14; 0.03 mg/kg group, n = 6) received dipper training consisting of three 50-min sessions. Each
daily session was initiated with the rat’s first head entry
into the receptacle. The probability of receiving 4 s access to water decreased from 0.267 to 0.05 per 60 s over
the three sessions. Acquisition training began the day
after the last dipper training session. Rats were injected
with CP 55,940 or vehicle 30-min before chamber placement. During each 20-min session, there were eight 15-s
light CS presentations. On CP 55,940 sessions, each offset of the light was followed immediately by 4-s access
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to water. Four different programs were used to vary the
timing of light presentations and water delivery. The
average time to the first light onset was 135 s (range of
90–180 s) with a mean intertrial interval of 120 s (range
of 74–165 s). On vehicle sessions, light presentations
were matched with those of CP 55,940 sessions and 4-s
“empty” intervals occurred in place of water deliveries
to ensure identical session length. CP 55,940 and vehicle sessions were intermixed randomly with the restrictions that no more than two of a session type occurred
in a row. The 0.01/0.03 mg/kg group received 60 training sessions at 0.01 mg/kg followed by 60 training sessions at 0.03 mg/kg CP 55,940; the 0.03 mg/kg group received 120 training sessions.
Dependent measures In the CS experiments, the primary
dependent measure was rate of dipper entries per second before the first water delivery. To allow for comparable measurement between drug (i.e., water) and vehicle (i.e., no water) sessions, the program types were
matched for timing of the intervals from which the dipper entry rate was taken. The dependent measure for
test sessions was the dipper entry rate in the first 2 min
of the test. To qualify to test, dipper entry rate on each
nicotine session was a minimum of 0.01 entries per second higher than each saline session within that testing
cycle. Rate of locomotor activity in the chamber (beam
breaks per second during the same interval as used for
dipper entries) was also analyzed. In feature-positive
experiments, the primary dependent measure was the
initial elevation score of a session. This score was calculated as the number of dipper entries recorded during the first 15-s presentation of the light CS minus the
number of dipper entries recorded during the 15-s interval before the light (CS period–pre-CS period). A positive value indicates more dipper entries during the CS.
Locomotor activity was also recorded throughout the
session.
Data analyses For acquisition, two-way repeated measures analyses of variance (ANOVAs) were conducted
with Drug (nicotine versus saline or CP 55,940 versus
vehicle) as one factor and Session as the other factor for
the dipper entry and activity measures. Generalization,
antagonism, and substitution tests were analyzed with
one-way repeated measures ANOVAs with Drug Dose
as the factor. Finally, the regeneration of the nicotine
generalization curves with CP 55,940 pretreatment were
examined with a two-way repeated measures ANOVA
using Drug (CP 55,940 or none) as one factor and Nicotine Dose as the other factor. Significant effects in substitution and antagonism ANOVAs were followed with
Tukey’s honestly significant difference (HSD) tests. Significant interactions in the two-way acquisition ANOVAs prompted selective use of paired t tests with Bonferroni’s correction to compare drug conditions within
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each session. Median effective doses [ED50s (95% confidence intervals)] were calculated using the least squares
linear regressions on nicotine generalization curves and
testing that resulted in full blockade of the CS effects of
nicotine. Statistical significance was declared when p <
0.05 for all tests. Only significant values are reported.
Results
Nicotine CS training and testing As shown in Figure 1a,
the discrimination was acquired by the eighth day of
training. This impression was supported by a significant

Figure 1. Panel a shows dipper entries per second before the
first water delivery on nicotine sessions compared to equivalent time on saline sessions. * denotes significant difference between nicotine and saline sessions. The inset graph of panel a
shows locomotor activity per second. Panel b shows dipper
entries per second during nicotine generalization tests. *denotes significant difference from the 0.2 mg/kg nicotine training dose. # denotes significant difference from saline (0 mg/kg
nicotine) responding. The inset graph of panel b shows the locomotor activity per second during generalization tests

J. E. M u r r a y

et al. in

P s y c h o p h a r m a c o l o g y 205 (2009)

Drug × Session interaction, F(13, 195) = 13.03, p < .001,
followed by paired t tests with Bonferroni’s correction
indicating that for sessions 4–14, dipper entries were
higher on nicotine than saline sessions, ts(15) ≥ 4.38, ps
< 0.001. Overall higher response levels on nicotine compared to saline was also supported by a main effect of
Drug, F(1, 15) = 100.49, p < 0.001. Although inspection
of the inset graph does not suggest a systematic effect of
nicotine on locomotor activity, there was a Drug × Session interaction, F(13, 195) = 1.84, p < .05. However, none
of the post-hoc comparisons were significant.
As shown in Figure 1b, conditioned responding diminished as the test dose of nicotine decreased from the
training dose (0.2 mg/kg) to saline [ED50 = 0.052 (0.03–
0.074) mg/kg]. There was a main effect of Drug Dose,
F(5, 75) = 17.93, p < 0.001. Follow-up Tukey’s HSD tests
found that 0.05, 0.1, and 0.2 mg/kg nicotine evoked
greater responding than saline, and that 0, 0.025, and 0.4
mg/kg evoked lower responding than the 0.2 mg/kg
training dose of nicotine, HSDmmd = 0.046. There was no
significant change in locomotor activity (inset graph) as
a function of nicotine dose.
Results from antagonism and substitution testing are
shown in Figure 2. During these phases, two rats were
removed from the study for failure to maintain the discrimination (n = 14). Pretreatment with increasing doses
of rimonabant decreased the nicotine-evoked CR (Figure 2a). The main effect of Drug Dose, F(4, 52) = 17.87,
p < 0.001, showed 1 and 3 mg/kg rimonabant decreased
nicotine-evoked responding compared to saline pretreatment, HSDmmd = 0.045 [ED50 = 1.09 (0.49–1.69) mg/
kg]. Of those two doses, 1 mg/kg was also different
from the vehicle baseline. Relative to vehicle pretreatment, the highest dose of rimonabant reduced nicotineinduced locomotor activity (inset graph), F(4, 52) = 4.15,
p < 0.01, to a level comparable to vehicle only, HSDmmd
= 0.078 (i.e., no nicotine).
There was an inverted U-shaped pattern of CP
55,940 substitution for the nicotine CS (Figure 2b).
There was a main effect of Drug Dose, F(4, 52) = 6.77,
p < 0.001. Conditioned responding on 0.01 mg/kg CP
55,940 was significantly higher than vehicle alone, HSDmmd = 0.028. This dose also differed from the 0.2 mg/
kg nicotine baseline. The 0.1 mg/kg dose of CP 55,940
reduced locomotor activity relative to vehicle alone
and nicotine (inset graph), F(4, 52) = 6.61, p < 0.001, HSDmmd = 0.06.
The dose of CP 55,940 that partially substituted for
the nicotine CS (0.01 mg/kg) was assessed to determine if it could shift the nicotine dose–effect curve. During this phase, one more rat was removed for poor discrimination performance (n = 13). As shown in Figure
2c, CP 55,940 appeared to enhance nicotine-appropriate responding. There was a main effect of Drug, F(1,
12) = 7.07, p < .001, and a Drug × Nicotine Dose interaction, F(3, 36) = 2.88, p < .05. CP 55,940 enhanced re-
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sponding to saline and to 0.1 mg/kg nicotine, HSDmmd
= 0.038 [ED50s = 0.043 (0.025–0.06) mg/kg for nicotine
alone; 0.049 (0.022–0.075) mg/kg for CP 55,940 pretreatment]. Although CP 55,940 showed partial substitution
for the training dose of nicotine twice and enhanced responding to a low dose of nicotine, these effects did not
translate into a shift in the ED50 for nicotine. A Type I error seems unlikely given the replication of partial substitution. The outcome may instead be a product of not
having enough test doses along the linear portion of the
dose–effect curves. Locomotor activity appeared relatively stable across nicotine doses (inset graph). However, there was a significant Drug × Nicotine Dose interaction, F(3, 36) = 5.39, p < 0.01; post-hoc comparisons
found no differences HSDmmd = 0.069.
CP 55,940 CS training When CP 55,940 was trained as
the CS, the discrimination was not acquired even when
training continued for twice as long as the nicotine CS
(Figure 3a). There was a significant Drug × Session interaction, F(27, 405) = 1.90, p < 0.01. However, none of
the comparisons were significant following Bonferroni’s
correction tests. Activity (Figure 3c) was similar regardless of drug treatment.
For rats that remained on CP 55,940 CS training, CP
55,940 evoked slightly higher levels of dipper entries
than vehicle (Figure 3b, top panel) as shown by a main
effect of Drug, F(1, 7) = 5.87, p < 0.05. Although this result suggests potential CS effects of CP 55,940, the discrimination was weak and not maintained throughout
training. There were no differences in activity for this
subset of rats (Figure 3d, top panel). In contrast, rats
switched to nicotine quickly acquired the discrimination
(Figure 3b, bottom panel). There was a significant Drug
× Session interaction, F(7, 49) = 14.74, p < 0.001. There
was more responding on nicotine than saline for sessions 31 and 33–36, ts(7) ≥ 3.88, ps < 0.0063. For activity
(Figure 3d, bottom panel), there was a significant Drug
× Session interaction, F(7, 49) = 2.25, p < 0.05. Nicotine
decreased activity on session 30, t(7) = 4.20, p < 0.0063.
CP 55,940 feature positive training: 0.01/0.03 mg/kg group
The light CS came to evoke a goal-tracking CR (Figure 4a). The main effect of Session supports the observation that dipper entries during the light presentations
steadily increased, F(29, 377) = 4.48, p < 0.001. However,
rats did not discriminate between 0.01 mg/kg CP 55,940
sessions (water reinforced) and the vehicle sessions
(non-reinforced). There was no main effect of Drug or
Drug × Session interaction. After switching from 0.01
mg/kg to 0.03 mg/kg CP 55,940, weak discrimination
performance emerged [main effect of Drug, F(1, 13) =
18.13, p < .001]. Response rates were stable across trials resulting in no main effect of Session or Drug × Session interaction. CP 55,940 evoked higher locomotor activity than vehicle at both training doses (Figure 4b). For

Figure 2. Panels a and b show dipper entries per second during rimonabant and CP 55,940 tests, respectively. Inset graphs
for each panel show locomotor activity per second during the
tests. *denotes significant difference from vehicle condition of
the given drug test. # denotes a further significant difference
from the control baseline (no nicotine for rimonabant and 0.2
mg/kg nicotine for CP 55,940). Panel c shows dipper entries
per second for pretreatment of a range of nicotine doses with
0.01 mg/kg CP 55,940. *denotes significant difference from the
same dose of nicotine with no pretreatment. The inset graph
shows locomotor activity per second
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Figure 3. Panel a shows dipper entries per second during 0.01 mg/kg CP 55,940 CS training. Panel b shows dipper entries per second for rats remaining on CP 55,940 training (top graph) and switched from CP 55,940 CS to nicotine CS training (bottom graph),
respectively. ^ denotes a significant main effect of CP 55,940 training without an interaction. * denotes significant difference between nicotine and saline sessions. Panel c shows locomotor activity during 0.01 mg/kg CP 55,940 CS training. Panels d show locomotor activity per second for rats remaining on CP 55,940 (top graph) and for rats switched from CP 55,940 to nicotine CS training (bottom graph), respectively. * denotes significant difference between nicotine and saline sessions

each dose, there were main effects of Drug, Fs ≥ 15.65, ps
≤ .002, but no main effect of Session or Drug × Session
interaction.
CP 55940 feature positive training: 0.03 mg/kg group Similar to the 0.01/0.03 mg/kg group, when rats were
trained with 0.03 mg/kg CP 55,940 from the outset a
very weak discrimination developed (data not shown).
There was a main effect of Drug, F(1, 295) = 6.97, p <
0.05, with the light CS evoking slightly higher initial elevation scores after CP 55,940 than vehicle administration. There was no effect of Session or Drug × Session
interaction. Locomotor activity was slightly higher on
CP 55,940 sessions than vehicle sessions, with an overall decrease in activity across sessions (data not shown).

These observations were supported by main effects of
Drug, F(1, 5) = 7.41, p < 0.05, and Session, F(59, 295) =
2.41, p < 0.001, and a Drug × Session interaction, F(59,
295) = 1.39, p < 0.05. However, after Bonferrroni’s correction, none of the comparisons were significant.
Discussion
Rats readily acquired the Pavlovian drug discrimination when 0.2 mg/kg nicotine was paired with a water US. This finding extends previous research from our
laboratory to a new US. Past research used food restriction and a sucrose US. The studies that used 0.2 mg/kg
nicotine as the training dose yielded similar to slightly
higher ED50s [from 0.049 in Murray and Bevins (2007a)
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Figure 4. Panel a shows initial elevation scores for rats trained with 0.01 mg/kg then 0.03 mg/kg CP 55,940 as a positive drug feature. Panel b shows locomotor activity during training. For both panels, ^ denotes a significant main effect of Drug without an
interaction

to 0.075 mg/kg in Reichel et al. (2007a)] than the 0.052
mg/kg nicotine found in the present study. We also
found a role for endocannabinoid activation in the expression of the interoceptive CS effects of nicotine.
Rimonabant partially blocked the CS effects of nicotine without affecting locomotor activity at 1 mg/kg. At
3 mg/kg, there was a concurrent reduction in locomotion and dipper entries, a finding that is potentially consistent with a response competition account of reduced
locomotion after administration of rimonabant (Tallett
et al. 2007). In that study, 1.5 and 3 mg/kg rimonabant
reduced locomotion while enhancing grooming and
scratching behaviors. Future research involving video
recording of behavior during test sessions would be
needed to assess this speculation. Our finding with the 1
mg/kg dose of rimonabant complements the well-documented role of endocannabinoids in the US or reinforcing effects of nicotine (e.g., Castañé et al. 2002; Kodas et

al. 2007). However, the results are in contrast to the operant drug discrimination literature. In those studies,
rimonabant at a range of 0.3 to 3 mg/kg (Cohen et al.
2002; Le Foll and Goldberg 2004) or even 5 to 10 mg/
kg (Zaniewska et al. 2006) did not affect the distribution
of nicotine-appropriate responding. In those studies, the
effect of rimonabant on rates of responding was mixed,
with two of the three studies showing no change in response rate (Le Foll and Goldberg 2004; Zaniewska et al.
2006). Furthermore, in the current study, 0.01 mg/kg CP
55,940 partially substituted for the training dose and enhanced responding to a low dose of nicotine. However,
in the operant-conditioning study by Zaniewska et al.
(2006), pretreatment with a higher dose of CP 55,940 (0.1
mg/kg) had no effect on nicotine discrimination performance or rate of responding.
There are several possible reasons for the differences
between the present studies and those just described.
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For instance, the dose of nicotine used as an SD was 0.4
mg/kg; the present study used 0.2 mg/kg nicotine as
the CS training dose. The 0.4 mg/kg dose during the nicotine generalization test did not evoke a CR (i.e., dipper
entries were at saline levels), a finding consistent with
the suggestion that the interoceptive stimulus effects of
0.2 mg/kg differ from 0.4 mg/kg. In Murray and Bevins
(2007a), 0.4 mg/kg also did not generalize to 0.2 mg/kg
nicotine. Additionally, extinction of the 0.4 mg/kg nicotine CS proceeded more slowly than the 0.2 mg/kg CS
(Murray and Bevins 2007b). Finally, in the operant drug
discrimination task, rats trained on 0.4 mg/kg learned
the discrimination faster than rats trained on 0.2 mg/
kg (cf. Chance et al. 1977). Another reason may be that
previous research with CP 55,940 or rimonabant and
the stimulus effects of nicotine used the two-lever operant-discrimination task with separate schedules of reinforcement in force depending on drug state. The present
research used a Pavlovian discriminated goal-tracking
task in which the reinforcer was made available independent of responding. If this distinction eventuates to
be important, then present results are the second neuropharmacological distinction found between the stimulus
effects of nicotine as a CS versus an SD. The first one was
described by Murray and Bevins (2007a). In that study,
the N-methyl-d-aspartate receptor channel blocker MK801 attenuated conditioned responding evoked by a nicotine CS. In contrast, nicotine-appropriate operant responding was unchanged after MK-801 pretreatment in
Zakharova et al. (2005) and Kim and Brioni (1995).
Because the interoceptive effects of CP 55,940 enhanced conditioned responding to the nicotine CS, we
hypothesized that this cannabinoid agonist would also
function as a CS. However, after twice the training as
that for nicotine, there was still no suggestion that conditioned responding was coming under control of the
CP 55,940 drug state. The subset of rats subsequently
switched to nicotine quickly acquired the Pavlovian discrimination. Thus, CP 55,940 shares some stimulus effects with nicotine as measured by partial substitution
for the nicotine CS and its enhancement of conditioned
responding to a low non-training dose of nicotine. The
stimulus effects of 0.01 mg/kg CP 55,940 itself, however, were not sufficient to function as a CS for access to
water. Notably, switching to nicotine training revealed
the locomotor-inhibiting effects of early nicotine exposure and suggests no cross-tolerance developed with CP
55,940 exposure.
Research from our laboratory has shown that thus
far, drugs other than nicotine (i.e., amphetamine, caffeine, and chlordiazepoxide) do not readily come to control a CR when trained as a CS (Murray et al. 2007; Palmatier and Bevins 2007). In contrast, up to this point,
every drug state tested by us has functioned as a positive drug feature occasioning when a discrete CS will
be reinforced. That list includes amphetamine, bupro-

J. E. M u r r a y

et al. in

P s y c h o p h a r m a c o l o g y 205 (2009)

pion, caffeine, chlordiazepoxide, cocaine, methamphetamine, and nicotine (Murray et al. 2007; Palmatier and
Bevins 2007; Reichel et al. 2007b; Wilkinson et al. 2008).
Further, midazolam was an effective positive drug feature disambiguating a context CS-shock US pairings in
rats (Maes et al. 1996). Midazolam, as well as amphetamine, were effective when trained as positive features for light CS–food pellet pairings in rats (Maes and
Vossen 1997). Troisi and Akins (2004) found that a cocaine-positive feature facilitated conditioned approach
behavior to a wood block CS paired with copulatory
opportunity in male quail. Finally, drugs such as morphine and fentanyl serve as positive drug features that
signal when a saccharin solution will be paired illness
(Jaeger and Mucha 1990; Skinner et al. 1998). Although
not an exhaustive list, clearly there is evidence that drug
states function as positive features. As such, we trained
CP 55,940 as a positive drug feature. Even though there
was clear evidence of biological activity of the CP 55,940
in the present study (e.g., altering activity, substituting
for nicotine, etc.), the drug did not reliably modulate (facilitate) conditioned responding to the light. This is the
first example of a drug with demonstrable SD effects (cf.
De Vry and Jentzsch 2003; Mauler et al. 2002) not functioning as a positive feature in our discriminated goaltracking task.
One of the compounds that functioned as a positive
feature in earlier research was chlordiazepoxide (e.g.,
Palmatier and Bevins 2008). The authors found that CR
topography changed when using a white noise rather
than a light CS. Rats were holding their heads in the
dipper receptacle longer rather than more often. There is
a detailed literature showing that conditioned response
form can vary as a function of stimulus modality (e.g.,
Bevins and Ayres 1991; Farwell and Ayres 1979). To determine whether the more-maintained head-poke CR
developed to the light CS on CP 55,940 sessions, we assessed the duration (rather than frequency) of dipper
entries. The pattern of results was no different than that
for the frequency of entries described in the “Results”
section. Thus, CP 55,940 did not appear to alter the response topography to the light CS in these studies.
Another potential explanation of the findings involves
the effects of exogenous cannabinoids on memory function (for reviews, see Davies et al. 2002; Ranganathan
and D’Souza 2006). For example, the CB partial agonist,
Δ9-tetrahydrocannabinol (THC; French 1997; Petitet et
al. 1998), has been shown to induce performance deficits
in the radial arm maze (Lichtman and Martin 1996) and
the Morris water maze (Da Silva and Takahashi 2002) in
rodents. Administration of rimonabant blocked the deficits in both tasks, indicating CB1 receptor specificity of
memory for the task. Additionally, intrahippocampal
infusions of CP 55,940 impaired performance in the radial arm maze (Lichtman et al. 1995), whereas infusions
of rimonabant enhanced water-maze performance (Rob-
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inson et al. 2008). Perhaps the impairment of acquisition in the present studies is due to the memory-deficit effects of cannabinoid activation. This seems unlikely
given our findings that CP 55,940 increased nicotine-appropriate responding, whereas rimonabant decreased
nicotine-appropriate responding. This pattern is the opposite of what would be expected had memory function
been the primary factor involved in the cannabinoid
modification of the nicotine CS. In addition, CP 55,940
effectively served as a SD indicating that it can acquire
control over behavior (e.g., Wiley et al. 1995a). Overall,
we are led to the conclusion that at the dose used, and
within the training conditions of the present research,
CP 55,940 is not effective as a Pavlovian stimulus (i.e., a
CS or positive feature).
Of course, acceptance of this conclusion without the
above caveat would be premature given that there are
numerous experimental parameters that could be manipulated. One example is the training dose. We started
with 0.01 mg/kg CP 55,940 because this dose significantly modified conditioned responding to the nicotine CS. The 0.01 mg/kg CP 55,940 is a relatively low
dose in the cannabinoid literature (cf. De Vry and Jentzsch 2003; Wiley et al. 1995a); a higher dose may be a
more effective drug feature. Indeed, a weak discrimination developed when the training dose was increased to
0.03 mg/kg CP 55,940. However, when the higher dose
of CP 55,940 served as the drug feature at the start of
training (i.e., 0.03 mg/kg group) discrimination performance was still weak and inconsistent. Although operant drug discrimination research has shown that 0.03
mg/kg CP 55,940 was sufficient to function as an SD (De
Vry and Jentzsch 2003; Mauler et al. 2002), perhaps an
even higher dose was needed in the Pavlovian positive
feature task. Another potential parametric change is to
increase the length of training. We trained the CP 55,940
CS for twice the number of sessions as the nicotine CS,
and the CP 55,940 positive features were trained for
more than twice that of the CP 55,940 CS. Further, De
Vry and Jentzsch (2003), as well as Mauler et al. (2002),
showed that rats acquired the 0.03 mg/kg CP 55,940
operant discrimination in a median of 38 training sessions (cf. to the 120 training sessions in the present CP
55,940 experiments). It seems unlikely that more training would have conditioned a stronger discrimination
in the present studies.
Overall, the results of the present research indicate a
mediating role of endocannabinoids in the nicotine CS.
However, the cannabinoid agonist, CP 55,940, does not
have Pavlovian stimulus effects using the current parameters. Because rimonabant does not alter schedulecontrolled responding by a nicotine SD (Cohen et al.
2002; Le Foll and Goldberg 2004; Zaniewska et al. 2006),
and because CP 55,940 functions as an effective operant SD at the doses used here (De Vry and Jentzsch 2003;
Mauler et al. 2002; Wiley et al. 1995a, b), the current re-
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search suggests a potential dissociation between the
mechanisms mediating operant and Pavlovian stimulus effects of nicotinic and cannabinoidergic compounds
that warrant further investigation (cf. Murray and Bevins 2007a).
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